<table>
<thead>
<tr>
<th>Date</th>
<th>Journal</th>
<th>Title</th>
<th>Study type</th>
<th>Country</th>
<th>Authors</th>
<th>Link</th>
<th>Intervention</th>
<th>Main question</th>
</tr>
</thead>
<tbody>
<tr>
<td>29-Jul-21</td>
<td>Blood</td>
<td>Frequency of positive anti P4/P4+polymer antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2</td>
<td>vaccine phase IV, RCT</td>
<td>Germany Thole T., et al.</td>
<td><a href="https://www.bloodjournal.org/content/10.1182/blood.2021038261">https://www.bloodjournal.org/content/10.1182/blood.2021038261</a></td>
<td>ChAdOx1 nCoV-19 or BNT162b2</td>
<td>To determine the frequency of anti-P4/P4+polymer antibodies in healthy vaccines and assess whether P4/P4+polymer EIA+ sera exhibit platelet-activating properties after vaccination with ChAdOx1 nCoV-19 (n = 138) or BNT162b2 (Biotech/Flonpol, n = 443).</td>
<td></td>
</tr>
<tr>
<td>6-Aug-21</td>
<td>The Lancet</td>
<td>Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenosine-vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial</td>
<td>RCT</td>
<td>UK</td>
<td>Xue et al.</td>
<td>ISRCTN, 68354519, Pfizer/Biontech and Ademarex-vaccine.</td>
<td>Safety and immunogenicity of heterologous schedules of the ChAd and BNT vaccines.</td>
<td></td>
</tr>
<tr>
<td>27-Jul-21</td>
<td>The Lancet Respiratory Medicine</td>
<td>Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRISCV): a randomised, controlled, open-label, adaptive platform trial</td>
<td>RCT</td>
<td>UK</td>
<td>Butler et al.</td>
<td>ISRCTN, 64534680, doxycycline</td>
<td>Efficacy of doxycycline to treat suspected COVID-19 in the community among people at high risk of adverse outcomes.</td>
<td></td>
</tr>
<tr>
<td>26-Jul-21</td>
<td>The Lancet Infectious Disease</td>
<td>Safety, tolerability, and immunogenicity of an aerosolised adenosine type-5 receptor vector COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial</td>
<td>RCT</td>
<td>China</td>
<td>Wu et al.</td>
<td>ISRCTN, 69552566, Ad5-nCoV vaccine</td>
<td>Evaluation of the safety and immunogenicity of the Ad5-nCoV vaccine by aerosol inhalation in adults.</td>
<td></td>
</tr>
<tr>
<td>25-Jul-21</td>
<td>Medrxiv</td>
<td>Safety and Immunogenicity of Nanovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine Phase 1 and phase 2 RCT</td>
<td>Phase 1 and phase 2 RCT</td>
<td>Vietnam</td>
<td>Nguyen et al.</td>
<td>ISRCTN, 66846384, Nanovax</td>
<td>Immunogenicity and safety of Nanovax vaccine</td>
<td></td>
</tr>
<tr>
<td>8-Aug-21</td>
<td>Medrxiv</td>
<td>Safety and Immunogenicity of QGP 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 1-2P Protein Vaccine MVC-21901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial</td>
<td>RCT</td>
<td>Taiwan</td>
<td>Su-Min et al.</td>
<td>ISRCTN, 64695652, MVC-COV1901 vaccine</td>
<td>Safety and immunogenicity of the COVID-19 vaccine MVC-COV1901.</td>
<td></td>
</tr>
<tr>
<td>28-Jul-21</td>
<td>Medrxiv</td>
<td>Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy</td>
<td>RCT</td>
<td>Netherlands</td>
<td>Rosen et al.</td>
<td>ISRCTN, 63715532, mRNA-1273 vaccine</td>
<td>Tolerability and safety of mRNA-1273 vaccine.</td>
<td></td>
</tr>
<tr>
<td>14-Jul-21</td>
<td>Medrxiv</td>
<td>Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 Phase 3 RCT</td>
<td>Phase 3 RCT</td>
<td>USA</td>
<td>Doogan M., et al.</td>
<td>ISRCTN, 69472501, Bamlanivimab plus Etesevimab</td>
<td>Primary outcome: overall clinical status of the patients, defined as Covid-19-related hospitalization or death from any cause by day 29.</td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Journal</td>
<td>Title</td>
<td>Details</td>
<td>URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-----</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14-Jul-21</td>
<td>NEJM</td>
<td>Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination</td>
<td>Correspondence: Netherland Barouch D.H., et al.</td>
<td>NCT04436276, Ad26.COV2.S vaccine To describe the 8-month durability of humoral and cellular immune responses in 20 participants who received the Ad26.COV2.S vaccine in one or two doses (either ≤5×1010 viral particles or ≥1011 viral particles) and in 5 participants who received placebo.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14-Jul-21</td>
<td>Nature Medicine</td>
<td>Immune responses against SARS-CoV-2 variants after heterologous and homologous SARS-CoV-2 vaccination</td>
<td>Brief Communication: Germany Barroso-Martins I. et al.</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-Jul-21</td>
<td>JAMA</td>
<td>Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 infection in Pregnant Women</td>
<td>Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 infection in Pregnant Women</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08-Jul-21</td>
<td>Lancet</td>
<td>Efficacy and safety of an inactivated whole-virus SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey</td>
<td>Efficacy and safety of an inactivated whole-virus SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey</td>
<td>NCT04551547, inactivated whole-virus SARS-CoV-2 vaccine (CoronaVac).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-Jul-21</td>
<td>JAMA</td>
<td>Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19</td>
<td>Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19</td>
<td>NCT04638213, canakinumab, an anti-interleukin-1β antibody. Is the anti-interleukin-1β antibody canakinumab effective to treat patients hospitalized with COVID-19 and hyperinflammation?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16-Jul-21</td>
<td>JAMA</td>
<td>Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection</td>
<td>Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection</td>
<td>NCT04332107, Azithromycin. To determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 34</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-Jul-21</td>
<td>JAMA</td>
<td>Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19</td>
<td>Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19</td>
<td>NCT04529125, IL-6 antagonists. To administration of IL-6 antagonists associated with 28-day all-cause mortality in patients hospitalized for COVID-19?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28-Jun-21</td>
<td>The Lancet Infectious Diseases</td>
<td>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled phase 1/2 clinical trial</td>
<td>RCT: China Han et al.</td>
<td>NCT04515147, CoronaVac vaccine Assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, Coronavirus in children and adolescents aged 3–17 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
19-Jun-21 International Journal of Infectious Diseases

A convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial

Bayesian re-analysis

UK

Hamilton IW et al.

NCT04801936

covaconvalescent plasma

To re-analyse of the data using Bayesian methods suggests there is a real possibility of benefit of convalescent plasma

16-Jun-21 NEJM

Tafaclobrate in Patients Hospitalised with Covid-19 Pneumonia

RCT

Brazil

Guimarães P.O. et al

NCT04469114

tafaclobrate

To evaluate efficacy and safety of tafaclobrate, a lipoxygenase inhibitor, in patients who are hospitalized with Covid-19 pneumonia.

9-Jun-21 Nature

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Re-using the samples collected from RCT

International

Alter G. et al

NCT04936276

Ad26.COV2.S vaccine

Study of the humoral and cellular immune responses induced by Ad26.COV2.S against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL 20C, P.1, and B.1.1.51 variants (Population enrolled at COVID19 phase 1/2 clinical trial).

12-Jun-21 International Immunopharmacology

Mometasone furoate nasal spray in the treatment of patients with COVID-19 allergic rhinitis: A randomised, double blind clinical trial

RCT

Iran

Hosseinifar

NCT201930404

mometasone furoate nasal spray

To evaluate the usage of mometasone furoate nasal spray in the recovery of patients with severe rhinorrhea or anosmia induced by COVID-19.

4-Jun-21 Lancet Respiratory Medicine

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

RCT

Brazil

Lopes et al

NCT04594377

rivaroxaban, enoxaparin, heparin

to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation

17-Jun-21 The Lancet Infectious Diseases

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

RCT

Netherlands

Arm et al

EudrACT 2020-001236-30

imatinib

Does imatinib reduce the time to discontinuation of ventilation and supplemental oxygen in patients with COVID-19?

28-Jun-2021 The Lancet Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (Coronavac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

RCT

China

Han et al

NCT04555147

CoronaVac vaccine

To assess the safety, tolerability, and immunogenicity of COVID-19 vaccine Coronavac in children and adolescents aged 5–17 years

25-Jun-2021 The Lancet

Immunogenicity and reactogenicity of BNT162b2 in children and adolescents (COMIRNATY): a multicentre, open-label, randomised, controlled, phase 2 trial

RCT

Spain

Bonilla et al

NCT04800739

CoronaVac (BNT162b2) vaccine

To assess the immunogenicity and reactogenicity of BNT162b2 (CoronaVac) in children and adolescents aged 12–15 years

9-Jun-2021 MedRxiv

Pyrrolidine in the treatment of adults with severe SARS-CoV-2 infection (PISSCO): a 2 randomised, double-blind, phase 2/3, placebo-controlled trial

RCT

Mexico

Fragoso-Saavedra et al

NCT04543953

pyrrolidine

to evaluate whether pyrrolidine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19

8-Jun-2021 MedRxiv

Safety and efficacy of antiviral therapy alone or in combination in COVID-19: a randomised controlled trial (DEV COVID Trial)

RCT

India

Singh et al

NCT04543953

To evaluate the therapeutic potential of hydroxychloroquine and lopinavir-ritonavir in combination with ribavirin in COVID-19

16-Jun-2021 MedRxiv

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Running title: REGEN-COV for COVID-19

RCT

UK

RECOVERY Group

NCT04801936

REGEN-COV (casirivimab and imdevimab)

To evaluate the efficacy and safety of REGEN-CO (a combination of 2 monoclonal antibodies (casirivimab and imdevimab)) that bind to two different sites on the receptor binding domain of the 26 SARS-CoV-2 spike protein) in patients admitted to hospital with COVID-19

8-Jun-2021 MedRxiv


RCT

UK

RECOVERY Group

NCT04801936

acetylsalicylic acid

To evaluate the effects of aspirin in patients hospitalised with COVID-19

27-May-2021 NEJM

Safety, Immuno-activity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

multination al, placebo-controlled, observed-blind trial

USA

Frenck RW et al

NCT04887270

BNT162b2 or placebo

To assess the safety (mortality and ad-verse events) and efficacy against confirmed COVID 19 > 7 days after dose 2 in the 12 to 15 year-old cohort

15-May-2021 NEJM

Interim Results of a Phase 3-2a Trial of Ad26.COV2.S Covid-19 Vaccine

multicenter, placebo-controlled, phase 3-2a trial

The Netherlands

Sadoff J et al

NCT04407626

Ad26.COV2.S vaccine

The safety and immunogenicity profiles of Ad26.COV2.S

21-May-2021 MedRxiv

Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomised controlled trial

single-blind, parallel-randomised controlled trial

Egypt

Elphage MA et al

NCT04502422

Sofosbuvir/ledipasvir (1:1, group) or control group (placebo, hydroxychloroquine, and Azithromycin (COH group))

To investigate the efficacy of Sofosbuvir/ledipasvir in the treatment of COVID-19 compared to the standard of care

4-May-2021 BMC Infectious Diseases Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients Prospective, randomized, controlled, single-blinded phase 3 study Turkey Okumuș et al. https://bmcinfect dis.biomedcentral.com/articles/10.1186/s12879-021-05637-8 NA ivermectin Ivermectin 200 μg/kg/day for 5 days in the form of a solution prepared for enteral use added to the reference treatment protocol: hydroxychloroquine + favipiravir. Patients in the control group were given only reference treatment with 3 other drugs without ivermectin.

To investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia, and to evaluate the effectiveness and safety of ivermectin use in the treatment of patients without mutation.


26-May-2021 Nature Med Safety and immunogenicity of IND-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, phase 2 clinical trial in adults at high risk of viral exposure Phase 2b CT USA Mammen et al. https://www.nature.com/articles/s41590-021-01097-0 NCT04642638 DNA vaccine (IND-4800) to assess the safety and immunogenicity of a DNA vaccine (IND-4800) targeting the full-length Spike antigen of SARS-CoV-2 when given to adults at high-risk of exposure.

18-May-2021 Nature Med Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19 RCT vaccine phase 1 Canada Ward B. et al. https://www.nature.com/articles/s41590-012-00370-1 NCT04560040 CVxLV (virus-like particle) vaccine candidates produced in plants To evaluate the short-term tolerability/safety and immunogenicity of CVxLV formulations assessed by neutralizing antibody (NAb) and cellular responses.

<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>Author(s)</th>
<th>Journal</th>
<th>Country</th>
<th>Study Design</th>
<th>Endpoint(s)</th>
<th>URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>14-May-21</td>
<td>Lancet</td>
<td>Consolamplene pla in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial</td>
<td>RECOVERY Collaborative Group</td>
<td>UK</td>
<td>RCT</td>
<td>To evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19</td>
<td><a href="https://www.thelancet.com/journals/lancet/ARTICLE/S0140-6736(21)00620-7/fulltext">https://www.thelancet.com/journals/lancet/ARTICLE/S0140-6736(21)00620-7/fulltext</a></td>
</tr>
<tr>
<td>21-May-21</td>
<td>Rev Invest Clin</td>
<td>Methyline Blue for Treatment of Hospitalized COVID-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2</td>
<td>Iran Harvey-Almadras</td>
<td>USA</td>
<td>RCT</td>
<td>To evaluate the effect of the reduced form of methylene blue (MB) on the improvement of oxygen saturation (SpO2) and respiratory rate (RR).</td>
<td><a href="https://www.elibrary.org/content/10.1016/j.2171-2150.2021.05.035.123690/2/fullpdf">https://www.elibrary.org/content/10.1016/j.2171-2150.2021.05.035.123690/2/fullpdf</a></td>
</tr>
<tr>
<td>15-May-21</td>
<td>BMJ</td>
<td>Effectiveness of the Pfizer-BioNTech and Oxfam/AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study</td>
<td>Observation and study UK Berral et al.</td>
<td>UK</td>
<td>NA</td>
<td>To estimate the real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxfam/AstraZeneca ChAdOx1-S vaccine against confirmed COVID-19 symptoms</td>
<td><a href="https://bmj.com/content/373/bmj.n1088">https://bmj.com/content/373/bmj.n1088</a></td>
</tr>
<tr>
<td>11-May-2021</td>
<td>J of Medical Virology</td>
<td>Effect of a combination of ritonavir, ribavirin, and interferon plus zinc supplement [MANS.NR2 study] on the clearance of mild COVID-19</td>
<td>Egypt Elaify H et al.</td>
<td>Egypt</td>
<td>CT</td>
<td>Combination of ritonavir, ribavirin, and interferon plus Zinc vs supportive treatment</td>
<td>To compare the rate and time of viral clearance in subjects receiving the combination of ritonavir, ribavirin, and interferon plus zinc versus those receiving supportive treatment.</td>
</tr>
</tbody>
</table>
| 20-Apr-2021 | MedRxivy                                                             | Pharmacokinetics and safety of XAV-21, a novel pyrrole-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase II study | France Gabonji B et al.           | France  | RCT           | XAV-10 0.5 mg/kg at day 1 and day 5 (group 1), 2 mg/kg at day 1 and day 5 (group 2), 2 mg/kg at day 1 and day 5 (group 3) or placebo | To assess the pharmacokinetics and safety of XAV-19, a novel pyrrole-humanized polyclonal antibody against SARS-CoV-2, in COVID-19-related moderate pneumonia. | https://www.medrxiv.org/content/10.1101/2021.04.15.21255549
| 5-May-2021 | MedRxivy                                                             | Pyridostigmine in adults with severe SARS-CoV-2 infection: the PISCO trial | Mexico Fragoso-Saezvedo S, et al. | Mexico  | RCT           | Pyridostigmine | To evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19 | https://www.medrxiv.org/content/10.1101/2021.05.03.21257404

**PubMed IDs:**
- [10.1101/2021.04.15.21255549](https://www.medrxiv.org/content/10.1101/2021.04.15.21255549)
- [10.1101/2021.05.03.21257404](https://www.medrxiv.org/content/10.1101/2021.05.03.21257404)
<table>
<thead>
<tr>
<th>Date</th>
<th>Source</th>
<th>Title</th>
<th>Study Type</th>
<th>Country</th>
<th>Description</th>
<th>Status (NCT#)</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-May-21</td>
<td>The Lancet</td>
<td>Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data</td>
<td>Observation study</td>
<td>Israel</td>
<td>Haas et al.</td>
<td>NA</td>
<td>BNT162b2 vaccine</td>
</tr>
<tr>
<td>5-May-21</td>
<td>The Lancet</td>
<td>Toxictumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial</td>
<td>RCT</td>
<td>UK</td>
<td>Horby et al. (RECOVERY Collaborative Group)</td>
<td>NCT04581936</td>
<td>Toxictumab</td>
</tr>
<tr>
<td>27-Apr-21</td>
<td>The Lancet Oncology</td>
<td>Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 in patients with cancer: interim analysis of a prospective observational study</td>
<td>Observation study</td>
<td>UK</td>
<td>Marnin et al.</td>
<td>NA</td>
<td>BNT162b2 vaccine</td>
</tr>
<tr>
<td>30-Mar-21</td>
<td>Lancet</td>
<td>Efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial</td>
<td>Vaccine</td>
<td>UK</td>
<td>Emary K.R.W., et al.</td>
<td>NCT04608388</td>
<td>ChAdOx1 nCoV19 (AZD1222) vaccine</td>
</tr>
<tr>
<td>10-Apr-21</td>
<td>BMC Infectious Diseases</td>
<td>Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blind randomized controlled trial</td>
<td>RCT</td>
<td>Iran</td>
<td>Ranjbar B</td>
<td>NCT04551790</td>
<td>Methylprednisolone or dexamethasone</td>
</tr>
<tr>
<td>8-Apr-2021</td>
<td>MedRxiv</td>
<td>Immunoenvigence and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomised, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials</td>
<td>Two phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC</td>
<td>China</td>
<td>Pan H et al.</td>
<td>NCT04756323</td>
<td>KCONVAC</td>
</tr>
<tr>
<td>1-Apr-2021</td>
<td>MedRxiv</td>
<td>INTERIM REPORT: SAFETY AND IMMUNOGENICITY OF AN INACTIVATED VACCINE AGAINST SARS-COV-2 2 HEALTHY CHILEAN ADULTS IN A PHASE 3 CLINICAL TRIAL</td>
<td>Intern analysis of a multicenter phase 3 CT</td>
<td>Chile</td>
<td>Bueno SM et al.</td>
<td>NCT04551790</td>
<td>Coronavirus</td>
</tr>
<tr>
<td>15-Apr-21</td>
<td>MedRxiv</td>
<td>Efficacy of a nasal spray containing latacarbapenem in the prophylaxis of COVID-19 in hospital personnel dedicated to patients with COVID-19 disease</td>
<td>RCT (CARR-COVID-19) trial group collaboration</td>
<td>Argentina</td>
<td>CARR-COVID-19 Trial group collaboration</td>
<td>NCT04521332</td>
<td>Nasal spray containing lata-carbapenem (1-C) or placebo for 21 days</td>
</tr>
<tr>
<td>15-Apr-21</td>
<td>MedRxiv</td>
<td>Performance of vaccination with Coronavirus in a cohort of healthcare workers (HCW) - preliminary report</td>
<td>(preliminary report)</td>
<td>Brazil</td>
<td>De Faria E et al.</td>
<td>N/A</td>
<td>Coronavirus</td>
</tr>
<tr>
<td>8-Apr-2021</td>
<td>IJ ClinicalMedicine</td>
<td>RBD-specific polyconal (Fye) 2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial</td>
<td>phase 2/3, double-blind, placebo-controlled, multicenter clinical</td>
<td>Argentina</td>
<td>Lopardo et al.</td>
<td>NCT04949694</td>
<td>Equine poly-clonal antibodies (FypA)</td>
</tr>
<tr>
<td>12-Apr-21</td>
<td>Int J Infectious Diseases</td>
<td>Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalised COVID-19 patients: a randomised clinical trial</td>
<td>double-blind, single-center study</td>
<td>Iran</td>
<td>Siemi Z et al.</td>
<td>NA</td>
<td>Diphenhydramine Compound (Diphenhydramine + Ammonium Chloride) is standard of care or Diphenhydramine alone and standard of care groups</td>
</tr>
<tr>
<td>15-Apr-21</td>
<td>Scientific reports</td>
<td>Role of interferon therapy in severe COVID-19: the CONFERRON randomized controlled trial</td>
<td>three-arm</td>
<td>Iran</td>
<td>Darzam IA et al.</td>
<td>NCT04537688</td>
<td>IFNa1a and IFNa1b</td>
</tr>
<tr>
<td>15-Apr-21</td>
<td>Scientific reports</td>
<td>Role of interferon therapy in severe COVID-19: the CONFERRON randomized controlled trial</td>
<td>three-arm</td>
<td>Iran</td>
<td>Darzam IA et al.</td>
<td>NCT04537688</td>
<td>IFNa1a and IFNa1b</td>
</tr>
</tbody>
</table>
24-Mar-21
The Lancet Infectious Diseases
Safety and immunogenicity of a recombinant tetravalent dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: a randomised, double-blind, placebo-controlled, phase 1 and 2 trials
RCT - vaccine - phase (i/ii)
USA
agarmathian P et al
https://jamanetwork.com/journals/jama/fullarticle/2777946
NCT04461946
ZF2001 vaccine subunit vaccine against COVID-19 using a dimeric form of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein as the antigen
To assess the safety and immunogenicity of this vaccine, ZF2001, and determine the appropriate dose and schedule for an efficacy study.

25-Mar-21
Therapeutic Advances in Respiratory Disease
Clinical effectiveness of drugs used in hospitalised patients with COVID-19: a systematic review and meta-analysis
meta-analyses
Mexico
De La Paz RA, et al
http://jamanetwork.com/journals/jama/fullarticle/2777948
NA
To assess the clinical effectiveness of drugs used in hospitalised patients with COVID-19 infection.

25-Mar-21
JAMA
Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxic Respiratory Failure The HENIVOT Randomized Clinical Trial
RCT International
Domenico Luca Greco
https://jamanetwork.com/journals/jama/fullarticle/2777949
NCT04502576
oxygen
To assess whether helmet noninvasive ventilation can increase the days free of respiratory support in patients with COVID-19 compared with high-flow nasal oxygen alone.

18-Mar-21
JAMA
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INTRICATE Randomized Clinical Trial
RCT Iran
INSPIRATION Investigators
https://jamanetwork.com/journals/jama/fullarticle/2777950
NCT04885088
enoxaparin, 1 mg/kg daily vs standard prophylactic anticoagulation mesoparin, 40 mg daily
To evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU).

8-Mar-21
Lancet Infect Dis
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, placebo-controlled, phase 1 trial
Vaccine trial - Phase (ii)
India
Elia R, et al
NCT04771539
BBV152 ( Bharat Biotech) vaccine
To evaluate the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152.

4-Mar-21
JAMA
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 Randomized Controlled Trial
RCT Phase (III)
Colombia/US A
Lopez-Medina E, et al
https://jamanetwork.com/journals/jama/fullarticle/2777951
NCT04905843
Ivermectin
To determine whether ivermectin is an efficacious treatment for mild COVID-19.

4-Mar-21
Lancet Respir Med
Sarilumab in patients admitted to hospital with severe or critical COVID 19: a randomised, double-blind, placebo-controlled, phase 3 trial
RCT Phase (III)
International
Lenzcare FL, et al
https://www.thelancet.com/journals/lancetrespiratory/article/PIIS2468-160X(20)30148-7/fulltext
NCT04273388
Sarilumab
To assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19.

4-Mar-21
Lancet
Astvithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
RCT Phase (III)
UK
PRINCIPLE Trial Collaborative Group
http://covid19-principle.lshtm.ac.uk/publication/2093840
NCT04065458
Astvithromycin
To assess the effectiveness of astvithromycin to treat suspected COVID-19 in people who have an increased risk of complications.

1-Mar-21
Antimicrob Agents Chemother
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
RCT Phase I
USA
Panter W. P., et al
https://asm.org/content/asm2020pisd-20125933 pdf
NCT04552210
Molnupiravir, EDD-1801, MA-4483, protising of the active ribonucleoside analog, 14-d3-n4- hydroxycytidine (NHC, EDD-1931)
Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1, randomised, double-blind, placebo-controlled study in healthy volunteers, which included evaluation of the effect of drug on food pharmacokinetics.

11-Mar-2021
JAMA
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Vaccine trial - Phase (I)
USA
Kathryn E. Stephenson
https://jamanetwork.com/journals/jama/fullarticle/2778050
NCT04886179
Ad26.COViD.2S Vaccine (Janssen)
To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses.

10-Feb-2022
Signal Transduct Target Ther
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial
Vaccine trial - Phase (ii)
China
Shi et al
https://jamanetwork.com/journals/jama/fullarticle/2778057
NCT04288100
Human umbilical cord-derived mesenchymal stem cells
To assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UCMSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data.

8-Feb-2022
Vaccine
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
RCT phase (II)
US
LaurenceChu
https://jamanetwork.com/journals/jama/fullarticle/2778059
NCT04090706
mRNA-1273 vaccine
To evaluate the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion stabilized spike protein of SARS-CoV-2.
**03-Mar-21**  
**Flos Med**  
Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial  
RCT  
Chile  
Baldoiis MA et al  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900346/
  
NCT04357098  
Convalescent Plasma  
To evaluate the efficacy and safety of early Convalescent Plasma therapy in COVID-19 progression

**07-Mar-21**  
**Thrombosis and Haemostasis**  
Squalene in the treatment of patients with early stages of COVID-19: a randomized controlled trial  
RCT  
Mexico  
Gonzalez-Ochoa AI et al.  
NCT05004674  
Squalene  
Reduced dose of squalene (500 IU) twice a day) in placebo for 21 days  
To evaluate the efficacy of squalene used in the early clinical stages of COVID-19

**16-Mar-21**  
**NEJM**  
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant  
South Africa  
Mathi SA et al.  
NCT04446474  
ChAdOx1 nCov-19 vaccine (AZD1222)  
To assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not infected with the human immunodeficiency virus (HIV) in South-Africa

**24-Feb-21**  
**NEJM**  
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting  
Vaccine  
Israel  
Dagan N. et al.  
N/A  
BNT162b2 mRNA Covid-19 Vaccine  
Evaluation of the effectiveness of the BNT162b2 mRNA vaccine based on data from Israel’s largest health care organization

**19-Feb-21**  
**Lancet**  
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomized trials  
Vaccine  
UK  
Vesey M. et al.  
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-9/fulltext  
N/A  
ChAdOx1 nCov-19 vaccine  
Exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses.

**18-Feb-21**  
**Lancet**  
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients  
Vaccine  
Israel  
Amir S. et al.  
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-9/fulltext  
N/A  
BNT162b2 vaccine  
To examine early reductions in SARS-CoV-2 infection and COVID-19 rates in vaccinated HCWs.

**28-Feb-21**  
**JAMA**  
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis  
Metaanalysis  
International  
Tamariz et al.  
https://jamanetwork.com/journals/jama/fullarticle/2777192  
N/A  
convalescent plasma  
Is treatment with convalescent plasma associated with improved clinical outcomes?

**17-Feb-21**  
**JAMA**  
Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial  
RCT  
Brazil  
Mural et al.  
https://jamanetwork.com/journals/jama/fullarticle/2272586  
NCT04449718  
Vitamin D3  
To investigate the effect of a single high dose of vitamin D3 on hospital length of stay in patients with COVID-19.

**12-Feb-21**  
**JAMA**  
Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection The COVID A to Z Randomized Clinical Trial  
RCT  
US  
Thomas et al.  
https://jamanetwork.com/journals/jama/fullarticle/2272788  
NCT04372327  
Zinc gluconate (50 mg), ascorbic acid (800 mg), both agents, or standard of care  
To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection.

**4-Feb-21**  
**JAMA**  
Povidone Iodine Mouthwash, Garlic, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial  
RCT  
France  
Guzevien  
https://jamanetwork.com/journals/jama/fullarticle/2272958  
NCT04371965  
Povidone iodine (PI) solutions  
Whether nasopharyngeal application of PI could reduce the viral load of patients with novel coronavirus disease 2019 (COVID-19) symptoms.

**22-Jan-21**  
**Respiratory**  
Early Use of Corticosteroids May Proteg SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients With COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial  
RCT  
China  
Tang et al.  
https://plosmedicine.org/doi/10.1371/journal.pmed.1903472  
NCT04373321  
methylprednisolone  
Safety and efficacy of corticosteroid given to the hospitalized patients with COVID-19

**Jan-21**  
**European Respirators Journal**  
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial  
RCT  
Brazil  
Rocco et al.  
https://fcctjournal.com/jour nanalysts/content/11/6/4/0  
NCT04552483  
nitazoxanide  
Efficacy and safety of nitazoxanide in COVID-19 patients

**Jan-21**  
**Stem Cell Transplantation in Medicine**  
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial  
RCT  
USA  
Lanzoni et al.  
https://ahemj.org/journal online/nano/article/10.1002/thor.20-0004  
NCT04935728  
mesenchymal stem cell  
Safety of MSC in COVID-19 patients

**1-Mar-21**  
**MedReiv**  
Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults  
RCT  
USA  
Neil Formica et al.  
NCT04583888  
NVX-CoV2373 vaccine  
Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373

**25-Jan-21**  
**Archives of Virology**  
Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study  
RCT  
Egypt  
Dalebous HM et al.  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461207/  
NCT04512995  
chloroquine and favipiravir  
To evaluate the efficacy of favipiravir

<table>
<thead>
<tr>
<th>Date</th>
<th>NEJM</th>
<th>Title</th>
<th>Country</th>
<th>Authors</th>
<th>URL</th>
<th>NCT Number</th>
<th>Funding/Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-Feb-21</td>
<td>NEJM</td>
<td>Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19</td>
<td>UK</td>
<td>Gordon AC et al</td>
<td>REMAP-CAP ClinicalTrials.gov number, NCT02739707</td>
<td>tocilizumab and sarilumab</td>
<td>To assess the efficacy of interleukin-6 receptor antagonists in critically ill patients with Covid-19</td>
</tr>
<tr>
<td>20-Jan-21</td>
<td>BMJ</td>
<td>Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial</td>
<td>Brasil</td>
<td>Veiga, V.C. et al</td>
<td><a href="https://www.bmj.com/content/372/bmj.n84">https://www.bmj.com/content/372/bmj.n84</a></td>
<td>NCT04403685</td>
<td>tocilizumab</td>
</tr>
<tr>
<td>11-Nov-20</td>
<td>Postgradual Medical Journal</td>
<td>Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)</td>
<td>India</td>
<td>Rastogi et al</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013312/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013312/</a></td>
<td>NCT04490247</td>
<td>Vitamin D</td>
</tr>
<tr>
<td>02-Feb-20</td>
<td>The Lancet</td>
<td>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</td>
<td>Russia</td>
<td>Logunov et al</td>
<td><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32658-2/full-text">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32658-2/full-text</a></td>
<td>NCT04530596</td>
<td>Gam-COVID-Vac (Sputnik V)</td>
</tr>
<tr>
<td>08-Dec-20</td>
<td>Lancet</td>
<td>Safety and efficacy of the DXYDX1 mCov-19 vaccine (ADD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</td>
<td>Multinational</td>
<td>Vripay et al</td>
<td><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32635-6/full-text">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32635-6/full-text</a></td>
<td>NCT04003838, NCT04444674</td>
<td>DXYDX1 mCov-19 vaccine</td>
</tr>
<tr>
<td>Date</td>
<td>NEJM</td>
<td>Title</td>
<td>Type</td>
<td>Country</td>
<td>Authors</td>
<td>Identifier</td>
<td>Description</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11-Dec-20</td>
<td>NEJM</td>
<td>Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19</td>
<td>RCT</td>
<td>USA</td>
<td>Kall A.C., et al.</td>
<td>NCT04021579</td>
<td>Baricitinib plus Remdesivir for hospitalized Adults with Covid-19</td>
</tr>
<tr>
<td>17-Dec-20</td>
<td>NEJM</td>
<td>Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia</td>
<td>RCT</td>
<td>USA</td>
<td>Salama et al.</td>
<td>NCT04372186</td>
<td>Tocilizumab To test the safety and efficacy of tocilizumab in hospitalized patients with Covid-19 pneumonia</td>
</tr>
<tr>
<td>31-Dec-20</td>
<td>Preprint</td>
<td>Exogenous Surfactant Versus Placebo in the Treatment of Moderate and Severe AIDs in COVID19: The Pilot Study of a Clinical Trial</td>
<td>RCT</td>
<td>Iran</td>
<td>Gahremani et al.</td>
<td>NCT02093210</td>
<td>surfactant Is surfactant effective in COVID-19 patients?</td>
</tr>
<tr>
<td>02-Dec-20</td>
<td>NEJM</td>
<td>Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results</td>
<td>Multinational</td>
<td>WHO Solidarity Trial Consortium</td>
<td>NCT04315940</td>
<td>Remdesivir, hydroxychloroquine (HCQ), lopinavir, and interferon beta-1a (IFN-β) for the treatment of COVID-19 patients</td>
<td></td>
</tr>
<tr>
<td>03-Dec-20</td>
<td>NEJM</td>
<td>Durability of Responses after SARS-CoV-2 mRNA1273 Vaccination</td>
<td>Phase I vaccine trial</td>
<td>USA</td>
<td>Widge A.T., et al.</td>
<td>NCT04283461</td>
<td>mRNA 1273 vaccine immunogenicity 3 months after second vaccination</td>
</tr>
<tr>
<td>24-Dec-20</td>
<td>Preprint</td>
<td>Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial</td>
<td>Phase I vaccine trial</td>
<td>USA/IR</td>
<td>Tabas et al.</td>
<td>NCT04366410</td>
<td>INO-4800 DNA vaccine Safety and immunogenicity of INO-4800 vaccine</td>
</tr>
<tr>
<td>17-Dec-20</td>
<td>NEJM</td>
<td>REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19</td>
<td>RCT</td>
<td>USA</td>
<td>Weirnecht D.M.</td>
<td>NCT04425629</td>
<td>REGN-COV2 antibody cocktail Interim study results: effects of high viral loads with complications and death from coronavirus disease 2019 (COVID-19) REGN-COV2 effects on outpatients</td>
</tr>
<tr>
<td>22-Dec-20</td>
<td>Preprint</td>
<td>Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 in phase 2, double-blind, randomised controlled trial and the persistence of immune responses from a phase 1 follow-up report</td>
<td>Phase II vaccine trial</td>
<td>India</td>
<td>Raches et al.</td>
<td>NCT04475159</td>
<td>Inactivated SARS-CoV-2 vaccine, BBV152 To test the immunogenicity and safety of BBV152: 3 μg and 6 μg with Alum–IMDC.</td>
</tr>
<tr>
<td>22-Dec-20</td>
<td>NEJM</td>
<td>A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19</td>
<td>RCT</td>
<td>Denmark</td>
<td>ACTIV-3/ICOV19 Study Group</td>
<td>NCT04501978</td>
<td>A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19</td>
</tr>
<tr>
<td>23-Dec-20</td>
<td>Trials</td>
<td>Interferon β-1a (IFN-β-1a) in COVID-19 patients (INTERCEPT): study protocol for a randomized controlled trial</td>
<td>RCT</td>
<td>Italy</td>
<td>Bosi et al.</td>
<td>NCT04409380</td>
<td>Interferon β-1a (IFN-β-1a) in COVID-19 patients To test the efficacy of interferon-β-1a (IFN-β-1a) in COVID-19 patients in an open-label, randomized clinical trial.</td>
</tr>
<tr>
<td>10-Dec-20</td>
<td>NEJM</td>
<td>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</td>
<td>Phase II vaccine trial</td>
<td>USA</td>
<td>Polack F.P., et al.</td>
<td>NCT04564736</td>
<td>BNT162b2 vaccine To evaluate the efficacy and safety of BNT162b2 in a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 spike protein.</td>
</tr>
<tr>
<td>16-Nov-2020</td>
<td>Critical Care Explorations</td>
<td>Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019</td>
<td>RCT</td>
<td>USA</td>
<td>George Sakoukas, et al.</td>
<td>NCT04111687</td>
<td>Intravenous Immunoglobulin To test the efficacy and safety of IV immunoglobulin in hospitalised COVID-19 patients.</td>
</tr>
</tbody>
</table>
Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized Controlled Trial

RCT Brazil Murai et al.

NCT04449738 Vitamin D3

To determine if vitamin-D3 supplementation can reduce hospital length of stay in hospitalized patients with severe COVID-19?

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

RCT USA Jagannathan et al.

NCT04318995 Peginterferon Lambda-1a

To determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lamba) could shorten the duration of viral shedding or symptoms in patients with mild to moderate COVID-19.

Prevention of severe COVID-19 in the elderly by early high-titer plasma

RCT Argentina Libster et al.

NCT04479163 Convalescent plasma

To evaluate the efficacy of convalescent plasma with high titers of SARS-CoV-2 antibody administered within 72 hours of mild symptoms to elderly patients with COVID-19.

A two-arm, randomized, controlled, multi-center, open-label Phase 2 study to evaluate the efficacy and safety of Itolizumab in the moderate to severe ARDS patients due to COVID-19

RCT India Kumar et al.

CTR/2020/05/24859 Itolizumab

To estimate the efficacy and safety of Itolizumab in the treatment of cytokine release syndrome in patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19.

5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results from a Randomized Double-Blind Placebo Controlled Interventional Trial in 130 SARSCoV-2 Positive Men

RCT Brazil, USA Caglianeri et al.

NCT04444629 Dutasteride

To determine if 5-alpha-reductase inhibitors (SARAs) are a beneficial treatment for COVID-19 if given after SARSCoV-2 infection.

Pentoxifylline decreases serum IL-6 levels and improves lymphocyte count in COVID-19 patients: Results from an external pilot study

RCT Mexico Malinonado et al.

COX-2 002945 Pentoxifylline

To test the effect of Pentoxifylline (PFX) on parameters such as IL-6, lymphocyte count, days of hospitalization, mortality, and the need for intubation on patients with severe and moderate COVID-19.

A Cluster Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

RCT Spain Mitija et al.

NCT04300453 Hydroxychloroquine

Does postexposure prophylaxis with hydroxychloroquine prevent SARS-CoV-2 infection?

A Randomized Trial of Convalescent Plasma in COVID-19 Severe Pneumonia

RCT Argentina Simonovich et al.

NCT04383535 Convalescent plasma

Is treatment with convalescent plasma associated with improved clinical outcomes in COVID-19 patients?

Safety and immunogenicity of ChAdOx1-nCoV-19 vaccine administered in a phase 1/2 trial in young and old adults (COVID02): single-blind, randomised, controlled, phase 1/2/3 trial

phase 1/2/3 vaccine trial UK Ramsay et al.

NCT04400836 ChAdOx1 vaccine

Safety and immunogenicity of ChAdOx1 vaccine in young and old adults

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomized, double-blind, placebo-controlled, phase 2/3 clinical trial.

LRI vaccine trial China Zhang et al.

NCT04512068 CoronaVac vaccine

Safety, tolerability and immunogenicity of CoronaVac vaccine

Randomized controlled trial of convalescent plasma therapy against standard therapy in 2 patients with severe COVID-19 disease

RCT Bahrain, Ireland Al Qahtani et al.

NCT04556534 Convalescent plasma

Pilot study designed to inform the design of a definitive phase 3 clinical trial.

Peginterferon Lambda for the treatment of COVID-19 in outpatients

RCT Canada Feld et al.

NCT04545259 Peginterferon

To evaluate a single subcutaneous injection of peginterferon-lambda in outpatients with COVID-19.

Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial

RCT Iran Tabarsi et al.

IARC2015122790 25726920 Intravenous Immunoglobulin

To investigate the potential usefulness of IVIG for the management of severe cases of Covid-19.

Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine? a Randomized, Multicenter Trial

RCT Egypt Sheneil Abd El Shafy et al.

NCT04447754 Zinc, Hydroxychloroquine

To evaluate the effect of combining chloroquine/hydroxychloroquine and zinc in the treatment of COVID-19 patients.
<table>
<thead>
<tr>
<th>Date</th>
<th>Journal</th>
<th>Title</th>
<th>Type</th>
<th>Country</th>
<th>Study Details</th>
<th>Subjects, Intervention, Outcomes</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 November</td>
<td>International Journal of Infectious Diseases</td>
<td>Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia</td>
<td>Preprint</td>
<td>Oman</td>
<td>Favipiravir, interferon beta-1b</td>
<td>To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia.</td>
<td><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572136/">Link</a></td>
</tr>
<tr>
<td>6 November</td>
<td>Clinical Infectious Diseases</td>
<td>Randomized, double-blind and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults</td>
<td>Preprint</td>
<td>China</td>
<td>Placebo, Vaccine</td>
<td>Phase 2 vaccine trial</td>
<td>NCT04412538</td>
</tr>
<tr>
<td>6 November</td>
<td>International Journal of Antimicrobial Agents</td>
<td>Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-2Q Study</td>
<td>Preprint</td>
<td>India</td>
<td>Placebo, Hydroxychloroquine</td>
<td>Hydroxychloroquine</td>
<td>NCT04408456</td>
</tr>
<tr>
<td>12-Nov-20</td>
<td>The Lancet Respiratory Medicine</td>
<td>Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial</td>
<td>RCT</td>
<td>UK</td>
<td>Placebo, Interferon beta-1a</td>
<td>IFN-beta 1a</td>
<td>NCT02000302</td>
</tr>
<tr>
<td>12-Nov-20</td>
<td>JAMA</td>
<td>Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 Randomized Clinical Trial</td>
<td>RCT</td>
<td>USA</td>
<td>Placebo, Fluvoxamine</td>
<td>Fluvoxamine</td>
<td>NCT04342665</td>
</tr>
<tr>
<td>23-Oct</td>
<td>MedRxiv</td>
<td>Efficacy of Convalescent Plasma Therapy compared to Fresh-Frozen Plasma in Severely Ill COVID-19 Patients: A Pilot Randomized Controlled Trial</td>
<td>RCT</td>
<td>India</td>
<td>Placebo, Convalescent Plasma</td>
<td>Convalescent Plasma</td>
<td>NCT04354466</td>
</tr>
<tr>
<td>27-Oct</td>
<td>MedRxiv</td>
<td>Controlled randomized clinical trial on using ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq</td>
<td>RCT</td>
<td>Iraq</td>
<td>Placebo, Ivermectin</td>
<td>Ivermectin + Doxycycline</td>
<td>NCT04551600</td>
</tr>
<tr>
<td>23-Oct</td>
<td>MedRxiv</td>
<td>Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-controlled phase 2 trial</td>
<td>RCT</td>
<td>China</td>
<td>Placebo, Human umbilical cord-derived mesenchymal stem cells</td>
<td>Human umbilical cord-derived mesenchymal stem cells</td>
<td>NCT04388102</td>
</tr>
<tr>
<td>26-Oct</td>
<td>Lancet pre-print</td>
<td>Umbilical Cord Mesenchymal Stem Cells for COVID-19 ARDS: A Double Blind, Phase 1/2a, Randomized Controlled Trial</td>
<td>RCT</td>
<td>USA</td>
<td>Placebo, Umbilical Cord Mesenchymal Stem Cells</td>
<td>Umbilical Cord Mesenchymal Stem Cells</td>
<td>NCT04355728</td>
</tr>
<tr>
<td>01-Nov</td>
<td>Lancet pre-print</td>
<td>Phase 3 Trial of Coronavirus (Favipiravir) in Patients With Mild to Moderate COVID-19</td>
<td>RCT</td>
<td>Russia</td>
<td>Placebo, Favipiravir</td>
<td>Favipiravir</td>
<td>NCT04501783</td>
</tr>
<tr>
<td>01-Nov</td>
<td>J Infectious Diseases</td>
<td>Treatment of Coronavirus Disease 2019 Patients With Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality</td>
<td>RCT</td>
<td>USA</td>
<td>Placebo, Convalescent Plasma</td>
<td>Convalescent Plasma</td>
<td>NCT04501783</td>
</tr>
<tr>
<td>Date</td>
<td>Source</td>
<td>Title</td>
<td>Study Type</td>
<td>Country</td>
<td>Investigators</td>
<td>Identifier</td>
<td>Efficacy and Safety of Tocilizumab in Patients Hospitalized with COVID-19</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
<td>---------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>23-Oct-20</td>
<td>NEJM</td>
<td>Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomised Clinical Trial</td>
<td>RCT</td>
<td>France</td>
<td>Hermine et al.</td>
<td>NCT04335807</td>
<td>Tocilizumab</td>
</tr>
<tr>
<td>20-Oct-20</td>
<td>ANMA Internal Medicine</td>
<td>Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19: Pneumonitis Randomized Clinical Trial</td>
<td>RCT</td>
<td>Italy</td>
<td>Salvarani et al.</td>
<td>NCT04346355</td>
<td>Tocilizumab</td>
</tr>
<tr>
<td>20-Oct-20</td>
<td>ANMA Internal Medicine</td>
<td>Efficacy of umifenovir in the treatment of mild and moderate covid-19 patients</td>
<td>Randomised clinical study</td>
<td>Russia</td>
<td>Yethinda et al.</td>
<td>NA</td>
<td>Umifenovir</td>
</tr>
<tr>
<td>01-Oct-20</td>
<td>International Journal of Research in Pharmacological Sciences</td>
<td>Effect of tocilizumab on the incidence of severe adverse events in COVID-19 patients</td>
<td>RCT</td>
<td>USA</td>
<td>John H. Beigel, et al.</td>
<td>NCT04287057</td>
<td>Tocilizumab</td>
</tr>
<tr>
<td>28-Oct-20</td>
<td>MedRxiv</td>
<td>Repurposed universal drugs for COVID-19 — interim WHO SOLIDARITY trial results</td>
<td>RCT</td>
<td>South Korea</td>
<td>Aleen Khurao, et al.</td>
<td>NCT05003971</td>
<td>Repurposed universal drugs for COVID-19 — interim WHO SOLIDARITY trial results</td>
</tr>
<tr>
<td>21-September-2020</td>
<td>International Journal of Allergy and Rhinology</td>
<td>Immunological profile of non-hospitalized patients with coronavirus disease 2019</td>
<td>RCT</td>
<td>USA</td>
<td>Carlos Salas, et al.</td>
<td>NCT04354201</td>
<td>Tocilizumab</td>
</tr>
<tr>
<td>21-October-2020</td>
<td>BMJ Infectious Diseases</td>
<td>The use of intravenous immunoglobulin gamma for the treatment of severe COVID-19 patients</td>
<td>RCT</td>
<td>Iran</td>
<td>Noor-Shahbargi, et al.</td>
<td>NCT02065017</td>
<td>Intravenous immunoglobulin gamma</td>
</tr>
<tr>
<td>29-September-2020</td>
<td>NEJM</td>
<td>Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults</td>
<td>Vaccine trial</td>
<td>USA</td>
<td>Egan L. Anderson, et al.</td>
<td>NCT04285461</td>
<td>mRNA-1273 vaccine</td>
</tr>
<tr>
<td>30-September-2020</td>
<td>NEJM</td>
<td>COVID-19 vaccine BNT162b1: elicits human antibody and T cell responses</td>
<td>Vaccine trial</td>
<td>Germany</td>
<td>Ugur Sahin, et al.</td>
<td>NCT04388701</td>
<td>BNT162b1 vaccine</td>
</tr>
<tr>
<td>4-September-2020</td>
<td>BMJ</td>
<td>Drug treatments for covid-19: living systematic review and network meta-analysis</td>
<td>Systematic review</td>
<td>Spain</td>
<td>Ane et al.</td>
<td>NCT04123923</td>
<td>Hydroxychloroquine</td>
</tr>
</tbody>
</table>

Efficacy of tocilizumab in Patients Hospitalized with COVID-19: A Randomised Clinical Trial (NCT04335807)

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomised Clinical Trial (NCT04346355)

Efficacy of umifenovir in the treatment of mild and moderate covid-19 patients (NCT04287057)

Rescue therapy for COVID-19 — Final Report (NCT04427501)

Repurposed universal drugs for COVID-19 — interim WHO SOLIDARITY trial results (NCT05003971)

Self-Priming in COVID-19 Patients on Low-flow Oxygen Therapy: A Cluster Randomized Controlled Trial (NCT04372188)

Immunological profile of non-hospitalized patients with coronavirus disease 2019 (NCT04354201)

The use of intravenous immunoglobulin gamma for the treatment of severe COVID-19 patients (NCT02065017)

Anti-Cytokine antibody Fc-p (vildoblimab) treatment versus best supportive care for patients with COVID-19 (PANACEA): an exploratory, open-label, phase 2 randomised controlled trial (NCT04333402)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (NCT04285461)

COVID-19 vaccine BNT162b1: elicits human antibody and T cell responses (NCT04388701)

Drug treatments for covid-19: living systematic review and network meta-analysis (NCT04123923)
26 Sept MedRxiv An in-depth investigation of the safety and immunogenicity of an inactivated 2 SAR-CoV-2 vaccine Phase 1 RCT China Pu et al. https://www.medrxiv.org/content/10.1101/2020.09.17.20212511.full.pdf NCT04412518 Vaccine To compare the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care.


20-Sep-20 eClinicalMedicine An open-label, randomized trial of the combination of IFN-kappa plus TF2 with standard care in the treatment of patients with moderate COVID-19 RCT China Fu et al. CHCTR20200000262 IFN-α, TF2 Efficacy and safety of IFN-α and TF2 in COVID-19 patients.


26 August 2020 Preprint Efficacy of commercial mouth-rinse on SARs-CoV-2 viral load in saliva: Randomized Controlled Trial in Singapore RCT Singapore Chooites, Suphapan, Sereyvuthong et al. https://www.mdpi.com/1424-8247/18/11/4093 full.pdf N/A Mouth wash To evaluate and compare different commercial mouthwash solutions and their effect on reducing salivary viral load

<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>Journal/Source</th>
<th>Methodology/Source</th>
<th>Country</th>
<th>Treatment/Intervention</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-Sep-20</td>
<td>Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial</td>
<td>European Respiratory Journal</td>
<td>RCT</td>
<td>Iran</td>
<td>Methylprednisolone</td>
<td>Is methylprednisolone effective in treatment of COVID-19 patients?</td>
</tr>
<tr>
<td>17-Sep-20</td>
<td>Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses</td>
<td>Plos Medicine</td>
<td>Meta-analyses</td>
<td>Denmark</td>
<td>NA</td>
<td>Effects of all treatment interventions for COVID-19</td>
</tr>
<tr>
<td>04-Sep-20</td>
<td>Safety and immunogenicity of an rAd5 and mAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia</td>
<td>The Lancet</td>
<td>RCT</td>
<td>Russia</td>
<td>Safety and immunogenicity of two formulations (frozen and lyophilised) of vaccine</td>
<td>Safety and immunogenicity of two formulations (frozen and lyophilised) of vaccine</td>
</tr>
<tr>
<td>10-Sep-20</td>
<td>Effect of recombinant human granulocyte colony-stimulating factor for patients with coronavirus disease 2019 (COVID-19) and lymphopenia: A randomised clinical trial</td>
<td>JAMA</td>
<td>RCT</td>
<td>China</td>
<td>NA</td>
<td>Do increased peripheral blood leucocyte and lymphocyte cell counts lead to clinical improvement in patients with COVID-19?</td>
</tr>
<tr>
<td>04-Sep-20</td>
<td>Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial</td>
<td>The Lancet</td>
<td>RCT</td>
<td>Brazil</td>
<td>Azithromycin</td>
<td>Would azithromycin improve clinical outcomes to COVID-19 patients?</td>
</tr>
<tr>
<td>03-Sep-20</td>
<td>Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis</td>
<td>Journal General Internal Medicine</td>
<td>Systematic review</td>
<td>India</td>
<td>NA</td>
<td>Is the use of CD or HCQ effective and safe in reducing mortality and improving the clinical course, fewer reconvalescence, and virologic clearance in COVID-19 patients?</td>
</tr>
<tr>
<td>02-Sep-20</td>
<td>Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoEX randomised controlled clinical trial</td>
<td>JAMA</td>
<td>RCT</td>
<td>Brazil</td>
<td>Dexamethasone</td>
<td>To determine whether intravenous dexamethasone increases the number of ventilation-free days among patients with COVID-19-associated ARDS.</td>
</tr>
<tr>
<td>02-Sep-20</td>
<td>Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis</td>
<td>JAMA</td>
<td>Meta-analysis</td>
<td>NA</td>
<td>Corticosteroids</td>
<td>To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality.</td>
</tr>
<tr>
<td>02-Sep-20</td>
<td>Safety and immunogenicity of an rAd5 and mAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia</td>
<td>Expert Review of Antiviral Therapy</td>
<td>Systematic review</td>
<td>UK</td>
<td>Safety and immunogenicity of two formulations (frozen and lyophilised) of vaccine</td>
<td>Safety and immunogenicity of two formulations (frozen and lyophilised) of vaccine</td>
</tr>
</tbody>
</table>

**Notes:**
- **RCT**: Randomized Controlled Trial
- **NA**: Not available
- **COVID-19**: Coronavirus Disease 2019
- **HCQ**: Hydroxychloroquine
- **CD**: Chloroquine
- **ARDS**: Acute Respiratory Distress Syndrome
- **COVID**: Coronavirus Disease
- **ICU**: Intensive Care Unit
<table>
<thead>
<tr>
<th>Date</th>
<th>Journal</th>
<th>Title</th>
<th>Country</th>
<th>Authors</th>
<th>URL</th>
<th>NCT Number</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 October 2020</td>
<td>BMJ</td>
<td>Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)</td>
<td>India</td>
<td>Arup Agarwal et al. and PLACID Collaborators</td>
<td><a href="https://www.bmj.com/content/371/bmj.m4358">https://www.bmj.com/content/371/bmj.m4358</a></td>
<td>NCT0465523</td>
<td>To assess the effectiveness of Convalescent plasma for the treatment of COVID-19 in Indian patients.</td>
</tr>
<tr>
<td>01-Sep</td>
<td>MedRxiv</td>
<td>Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial</td>
<td>Spain</td>
<td>Armando Sobrino et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.08.27.20203362v2.full.pdf">https://www.medrxiv.org/content/10.1101/2020.08.27.20203362v2.full.pdf</a></td>
<td>NCT04431059</td>
<td>To demonstrate the efficacy and safety of Convalescent Plasma used to prevent progression to severe disease or death in hospitalized patients with earlier forms of COVID-19.</td>
</tr>
<tr>
<td>09-Sep</td>
<td>MedRxiv</td>
<td>Early oral clearance among COVID-19 patients when gargling with Povidone-Iodine and Essential oils – a clinical trial</td>
<td>Malaysia</td>
<td>Noel Amassawi Mohammed et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.08.27.20203362v2.full.pdf">https://www.medrxiv.org/content/10.1101/2020.08.27.20203362v2.full.pdf</a></td>
<td>NCT04431059</td>
<td>To assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx.</td>
</tr>
<tr>
<td>12/08/2020</td>
<td>MedRxiv</td>
<td>Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia</td>
<td>USA</td>
<td>Rosas et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.08.27.20203362v2.full.pdf">https://www.medrxiv.org/content/10.1101/2020.08.27.20203362v2.full.pdf</a></td>
<td>NCT04520015</td>
<td>To investigate whether tocilizumab has clinical benefit in hospitalized patients with severe COVID-19 pneumonia.</td>
</tr>
<tr>
<td>10-Sep</td>
<td>BMJ Infectious Diseases</td>
<td>Patient-Reported Health Outcomes After Treatment of COVID-19 With Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical Care alone: A Randomized, Open-Label, Controlled Trial</td>
<td>Cuba</td>
<td>Delgado-Enos et al.</td>
<td><a href="https://publications.nature.com/articles/s41551-020-02482-z">https://publications.nature.com/articles/s41551-020-02482-z</a></td>
<td>RPICE00000316</td>
<td>Neutral electrolyzed saline to evaluate the efficacy of treatment with intranasal and/or reduced neutral electrolyzed saline combined with usual medical care versus usual medical care alone, in ambulatory patients with COVID-19.</td>
</tr>
<tr>
<td>13 August 2020</td>
<td>JAMA</td>
<td>Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immune Responses in Patients With Moderate COVID-19</td>
<td>China</td>
<td>Shengli Xia, et al.</td>
<td><a href="https://jamanetwork.com/journals/jama/fullarticle/27705817">https://jamanetwork.com/journals/jama/fullarticle/27705817</a></td>
<td>NCT02000034</td>
<td>Inactivated vaccine To assess the safety and immunogenicity of this whole virus inactivated vaccine</td>
</tr>
<tr>
<td>Date</td>
<td>Source</td>
<td>Title</td>
<td>Type</td>
<td>Region</td>
<td>Authors</td>
<td>URL</td>
<td>NA</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>28 Aug</td>
<td>MedRxiv</td>
<td>RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study</td>
<td>Systematic Review</td>
<td>USA/ Germany</td>
<td>Walsh et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/">https://www.medrxiv.org/content/10.1101/</a> 2020.08.18.20193855</td>
<td>NCT04388728</td>
</tr>
<tr>
<td>6 Aug</td>
<td>JMF</td>
<td>Systematic Review and Meta-analysis of Efficacy of Treatment Options Against SARS-CoV-2 Infection</td>
<td>Systematic review</td>
<td>USA</td>
<td>Veselka Chandra, et al.</td>
<td><a href="https://www.nature.com/articles/srep201500567">https://www.nature.com/articles/srep201500567</a></td>
<td></td>
</tr>
<tr>
<td>20-July</td>
<td>Lancet</td>
<td>Safety and Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial</td>
<td>RCT</td>
<td>UK</td>
<td>Fabozzi et al., on behalf of the Oxford COVID Vaccine Trial Group</td>
<td><a href="https://www.thelancet.com/doi/10.1016/j">https://www.thelancet.com/doi/10.1016/j</a>. 2020.05.06.200338</td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- **RCT:** Randomized Controlled Trial
- **NA:** Not Available
- **URL:** Website URL
- **BMJ:** British Medical Journal
- **MedRxiv:** Preprint server for preprints in the field of health sciences
- **NEJM:** New England Journal of Medicine
- **JMF:** Journal of Medical Virology
- **Lancet:** The Lancet
null
<table>
<thead>
<tr>
<th>Date</th>
<th>Journal</th>
<th>Title</th>
<th>Country</th>
<th>Authors</th>
<th>URL</th>
<th>Result/Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-Jun</td>
<td>medRxv</td>
<td>GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia</td>
<td>Spain</td>
<td>Carral-Guzino et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.07.17.20131579">link</a></td>
<td>Randomized controlled trial (EudraCT number: 2020-001954-37) methylprednisolone</td>
</tr>
<tr>
<td>05-Jun</td>
<td>Science Immunology</td>
<td>Inhibition of Bruton tyrosine kinase in patients with severe COVID-19</td>
<td>USA</td>
<td>Roschewski et al.</td>
<td><a href="https://immunoregulatory.cs.duke.edu">link</a></td>
<td>Is acalabrutinib effective in severe COVID-19 patients?</td>
</tr>
<tr>
<td>8 June 2020</td>
<td>Accelerated publication</td>
<td>Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe</td>
<td>UK</td>
<td>Seth Flaxman et al.</td>
<td><a href="https://www.natmed.org/articles/141386-022-2405-7">link</a></td>
<td>Non-pharmaceutical interventions were effective in limiting the spread of SARS-CoV-2</td>
</tr>
<tr>
<td>8 May 2020</td>
<td>Nature Lymphoma</td>
<td>The Junos kinase 1/2 inhibitor nuspilisib in COVID-19 with systemic hyperinflammation</td>
<td>Germany</td>
<td>T. La Rosie, et al.</td>
<td><a href="https://www.nature.com/articles/s41586-020-0951-0">link</a></td>
<td>Nuspilisib</td>
</tr>
<tr>
<td>10-Jun</td>
<td>BMJ</td>
<td>Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross-sectional study</td>
<td>China</td>
<td>Min Liu et al.</td>
<td><a href="https://bmj.com/content/20/6/28">link</a></td>
<td>NA</td>
</tr>
<tr>
<td>02-Jun</td>
<td>The Lancet Digital Health</td>
<td>Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study</td>
<td>UK</td>
<td>Gaynes et al.</td>
<td><a href="https://www.thelancet.com/journals/thnet/article/PIIS2468-2012-00015-4/fulltext">link</a></td>
<td>NA</td>
</tr>
<tr>
<td>26-May</td>
<td>Clinical Microbiology and Infection</td>
<td>Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review</td>
<td>Australia/Sri Lanka</td>
<td>Rodrigo et al.</td>
<td><a href="https://www.sciencedirect.com/science/article/pii/S1199430920303533">link</a></td>
<td>NA</td>
</tr>
<tr>
<td>14-Jun</td>
<td>MedRxv</td>
<td>Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests</td>
<td>Belgium</td>
<td>Herreolens et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.08.09.20247795">link</a></td>
<td>N/A</td>
</tr>
<tr>
<td>09-Jun</td>
<td>MedRxv</td>
<td>Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience</td>
<td>Cuba</td>
<td>Pereda et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.05.29.20200299">link</a></td>
<td>RIPCECC00000312</td>
</tr>
<tr>
<td>10-Jun</td>
<td>MedRxv</td>
<td>ION (Ivermectin in Covid Nineteen) study: Use of ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19</td>
<td>USA</td>
<td>Cepielawicz Rajer et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.05.28.20244626">link</a></td>
<td>N/A</td>
</tr>
<tr>
<td>14-Jun</td>
<td>MedRxv</td>
<td>First Clinical Use of Lenalumab to Neutralize SARS-CoV-2 in Patients with Severe and Critical COVID-19 Pneumonia</td>
<td>USA</td>
<td>Temengen et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.06.08.20218869">link</a></td>
<td>N/A</td>
</tr>
<tr>
<td>02-Jun</td>
<td>MedRxv</td>
<td>Low-level of the prognostic biomarker sPAP are predictive of m mortality in patients with symptoms of COVID-19 - a prospective cohort study</td>
<td>Denmark/UA A</td>
<td>Eugen-Ohlen et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.07.30.20214746">link</a></td>
<td>N/A</td>
</tr>
<tr>
<td>08/2020</td>
<td>MedRxv</td>
<td>Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day 7 Interim Analysis of a Registered Clinical Trial</td>
<td>USA</td>
<td>Hess et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.08.13.20199891">link</a></td>
<td>N/A</td>
</tr>
</tbody>
</table>

08-Jun MedRxiv Nacio short peptide nutrition intervention on the prognosis of patients with COVID-19 Retrospectiv e analysis China Zhang et al. https://www.me drxiv.org/content/ 10.1107/2020. 03.29.20144229 v3 full.pdf N/A Tensile nutrition To explore the effect of high fiber whey short peptide external nutrition on the prognosis of patients with COVID-19.


02-Jun MedRxiv A cohort study to evaluate the effect of combined Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients. Observation al study Singapore Chuan Wen Tan et al. https://www.me drxiv.org/content/ 10.1107/2020. 03.30.20177929 v3 full.pdf N/A Vitamin D, Magnesium and Vitamin B12 (DMB) To determine the clinical outcomes of older COVID-19 patients who received Vitamin D, Magnesium and Vitamin B12 (DMB) compared to those who did not.


02/06/2020 MedRxiv Rapid point of care nucleic acid testing for SARS-CoV-2 in hospitalised patients: a clinical trial and implementation study prospective clinical trial and observation al study UK/South Africa Darn Coller et al. https://www.me drxiv.org/content/ 10.1107/2020. 03.30.20177929 v3 full.pdf N/A Antibody diagnostic To compare Samba II SARS-CoV-2 performance against the standard lab-RT-PCR test in suspected COVID-19 cases presenting to hospital, followed by a hospital-based implementation study.

06-Jun MedRxiv Side by side comparison of three fully automated SARS-CoV-2 antibody assays with focus on specificity Diagnostic comparison Austria Perlmann et al. https://www.me drxiv.org/content/ 10.1107/2020. 03.30.20177929 v3 full.pdf N/A Antibody diagnostic To compare three fully automated large-scale laboratory analyzer test systems, with particular emphasis on specificity, which is crucial for an adequate positive predictive value given the current low seroprevalence worldwide.

05-Jun MedRxiv Implementation and evaluation of a novel real- time multiplex assay for SARS-CoV-2 in-field learning from a clinical microbiology laboratory Diagnostic validation study Australia Williams et al. https://www.me drxiv.org/content/ 10.1107/2020. 03.30.20177929 v3 full.pdf N/A Nucleic acid diagnostic To describe initial experience using a commercially-available multiplex two-step nested tandem RT-PCR assay for the detection of coronaviruses that infect humans, including SARS-CoV-2.

02-Jun MedRxiv Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay Diagnostic validation USA/Scotland and India Dash et al. https://www.me drxiv.org/content/ 10.1107/2020. 03.29.20105962 v3 full.pdf N/A Diagnostic for identifying suitable Convalescent plasma donors To construct and validate a cell-free assay to measure neutralizing antibodies in order to identify suitable donors of convalescent plasma.


06-Jun-20 Brains, Behaviour and Immunity Poor sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalised patients with COVID-19: A retrospective cohort study Retrospectiv e study China Zhang et al. https://www.sci ence.org/content/articles/ 10.1126/scienc 369.6656.0130 NS155.1 v3 full.pdf N/A NA Effects of sleep quality on recovery from lymphopenia and clinical outcomes in hospitalised patients with COVID-19.


May 2020 PlosOne

2020-07-08: A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for COVID-19

RCT USA / Canada D.R. Boulware, et al. NCT04388688 Hydroxychloroquine

12 June 2020 Lancet

2020-06-29: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

RCT International collaboration J.I. Seigel, et al. NCT04927670 Remdesivir


RCT International collaboration J.I. Seigel, et al. NCT04927670 Remdesivir

2020-07-08: Anakinra for severe forms of COVID-19: a cohort study

Cohort study France Huet et al. N/A Anakinra

2020-07-08: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

CT China Feng-Cai Zhu et al. NCT04313327 Ad5 vectored COVID-19 vaccine

2020-07-08: A comparative study on the time to achieve negative nucleic acid testing and hospital stay between Darzapir and Lopinavir/Ritonavir in the treatment of patients with COVID-19

Comparative study China Zhiheng Zhang et al. N/A Darzapir and lopinavir/ritonavir

2020-07-08: Interferon-beta-1a as a Candidate for COVID-19 Treatment; An Open-label Single-Arm Clinical Trial

CT Iran Payandemehr et al. NCT02039140 Interferon beta-1a

2020-07-08: Efficacy and safety of interferon-beta-1a in treatment of severe COVID-19: A randomised clinical trial

RCT Iran Ozavadi-Morvarid et al. NCT02038238 Interferon beta-1a

2020-07-08: A serological assay to detect SARS-CoV-2 antibodies in at-home collected fingerprick dried blood spots

Clinical Evaluation of diagnostic test USA Karp et al. IRB protocol #01803015 Antibody diagnostic test

2020-07-08: Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2

Clinical Evaluation of diagnostic test UK/USA/South Africa Assenato et al. N/A Nucleic acid diagnostic test
20/05/2020 medRxiv EasyCOV - LAMP based rapid detection of SARS-CoV-2 in saliva Clinical evaluation of diagnostic test France L’Helguerchat et al. https://www.medrxiv.org/content/10.1101/2020.05.20.20117125.full.pdf N/A saline RT-LAMP diagnostic test To develop and clinically evaluate a new simple saline SARS-CoV-2 detection test based on RT-LAMP technology

27/05/2020 medRxiv Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM/IgG Combined Antibody Tests Clinical evaluation of diagnostic test France Prassuck et al. https://www.medrxiv.org/content/10.1101/2020.05.27.20118986.full.pdf N/A Antibody rapid diagnostic test To evaluate the performance of two COVID-19 IgM/IgG Rapid Diagnostic Tests compared to the gold standard, RT-PKR.

19/05/2020 medRxiv Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single-arm multicenter interventional trial Proof of concept study Italy Perrotti et al. NCT04321411 convalescent plasma To show the potential efficacy and safety of hyperimmune plasma infusions, obtained from convalescent donors, in COVID-19 patients with respiratory failure

26/05/2020 medRxiv Use of High Flow Nasal Therapy to Treat Moderate to Severe Hypoventilatory Respiratory Failure in COVID-19 Retrospective analysis USA Patel et al. https://www.medrxiv.org/content/10.1101/2020.05.26.20113373.full.pdf N/A High Flow Nasal Therapy To analyse the outcomes of COVID-19 patients with moderate-to-severe hypoventilatory respiratory failure receiving High Flow Nasal Therapy

22-May-20 The Lancet Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Observation study USA/Switzerland and Mehra et al. https://www.thelancet.com/journal/supplementary/Pdfs/PIIS0140 6736(20)31030 6/full.pdf N/A Hydroxychloroquine Are these treatment regimens associated with in-hospital death?


19 May 2020 Clinical Infectious Diseases Early Short Course Corticosteroids in Hospitalised Patients with COVID-19 Retrospective study USA Fidel et al. NCT04374071 corticosteroids To examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19.


14 May 2020 Lancet Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study Randomized crossover trial Spain Francisco de la Abaja et al. https://www.thelancet.com/content/10.1016/S0140 6736(20)31075 4 N/A renin-angiotensin-aldosterone system inhibitors, RAAS Does use of RAAs predispose patients to severe COVID19?

Preprint Cardiology Journal Resuscitation of the patient with suspected/confirmed COVID-19: A randomised multicenter crossover simulation trial Randomized crossover trial Poland Marak-Malysz et al. https://journal.of.resuscitation.elsevierjourналs.com/article/S0300 7932(20)30284 6 N/A PPE To evaluate various methods of chest compressions in patients with suspected/confirmed SARS-CoV-2 infection conducted by medical students wearing full personal protective equipment (PPE) for aerosol generating procedures (AGP).


19 May 2020 Nature Artificial intelligence–enabled rapid diagnosis of patients with COVID-19 Diagnostic assay China Xiuyan Mei et al. https://www.ncbi.nlm.nih.gov/articles/PMC7434147 N/A Artificial algorithm Can an AI model rapidly identify SARS-CoV-2 infection based on initial CT scans and associated clinical information of COVID-19 (n) patients in the early stage?

23-May 2020 Medrxiv Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19 Retrospective analysis South Korea Sang Youl Rhee et al. https://www.medrxiv.org/content/10.1101/2020.05.20.20089553.full.pdf N/A Dipeptidyl peptidase-4 (DPP-4), renin-angiotensin system (RAS) blockade To investigate the effects of dipeptidyl peptidase-4 (DPP-4) and renin-angiotensin system (RAS) blockade on the short-term clinical outcomes of COVID-19

23-May 2020 Medrxiv Do COVID-19 patients admitted to the ICU require anti-Pneumocystis pneumonia prophylaxis? Prospective cohort study France Aliaro https://www.medrxiv.org/content/10.1101/2020.05.18.20019396.v1.full.pdf N/A anti-Pneumocystis jirovecii prophylaxis To investigate the prevalence of Pneumocystis jirovecii in COVID-19 patients admitted to the ICU

23/05/2020 Medrxiv Development and clinical application of a rapid and sensitive loop-mediated isothermal amplification test for SARS-CoV-2 infection Diagnostic study China Hu et al. https://www.medrxiv.org/content/10.1101/2020.05.23.20088832 N/A RT-LAMP Diagnostic test To develop and validate a novel RT-LAMP assay capable of detecting SARS-CoV-2 RNA for potential use in centralized facilities and point-of-care settings
<table>
<thead>
<tr>
<th>Date</th>
<th>Source</th>
<th>Title</th>
<th>Study Design</th>
<th>Country</th>
<th>Study Details</th>
<th>Phase</th>
<th>Study Type</th>
<th>Study Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>22 May 2020</td>
<td>Medrxiv</td>
<td>Use of silimubin in patients with COVID-19 pneumonia requiring ventilatory support</td>
<td>Retrospective analysis</td>
<td>Italy, UK</td>
<td>Gritti et al.</td>
<td>NCT04322188</td>
<td>Silimubin</td>
<td>Efficacy of silimubin for treatment of severe patients with COVID-19</td>
</tr>
<tr>
<td>22 May 2020</td>
<td>Medrxiv</td>
<td>Almitrine as a non ventilatory strategy to improve intra-thoracic shunt in COVID-19 patients</td>
<td>Case control series</td>
<td>France</td>
<td>Losser et al.</td>
<td>N/A</td>
<td>Almitrine</td>
<td>To test if intravenous almitrine can improve hypoxia in mechanically ventilated COVID-19 patients</td>
</tr>
<tr>
<td>12 May 2020</td>
<td>Medrxiv</td>
<td>Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment</td>
<td>Systematic review</td>
<td>UK</td>
<td>Daves et al.</td>
<td>N/A</td>
<td>Remdesivir</td>
<td>To examine the benefit-risk profile of remdesivir in COVID-19 patients compared to standard of care, placebo or other treatments</td>
</tr>
<tr>
<td>15 May 2020</td>
<td>Medrxiv</td>
<td>Assisting Scalable Diagnosis Automatically in CT Images in the Combat against COVID-19</td>
<td>Application of deep learning to retrospective analysis</td>
<td>China</td>
<td>Liu et al.</td>
<td>N/A</td>
<td>Chest CT</td>
<td>To test the hypothesis that application of deep learning to 3D chest CT images could help identify COVID-19 infections</td>
</tr>
<tr>
<td>15 May 2020</td>
<td>Medrxiv</td>
<td>The effects of ABAs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents</td>
<td>Retrospective analysis</td>
<td>Belgium</td>
<td>De Spiegeler et al.</td>
<td>N/A</td>
<td>ABAs, ACEIs, Statins</td>
<td>To explore the association of ACEI/ARB and/or statins with clinical manifestations in COVID-19 infected older people residing in nursing homes</td>
</tr>
<tr>
<td>14 May 2020</td>
<td>Medrxiv</td>
<td>Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients</td>
<td>Expanded access program</td>
<td>USA</td>
<td>Joycey et al.</td>
<td>NCT0433850</td>
<td>Convalescent plasma</td>
<td>To analyze key safety metrics following transfusion of convalescent plasma in patients with severe or life-threatening COVID-19</td>
</tr>
<tr>
<td>13 May 2020</td>
<td>Medrxiv</td>
<td>Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas</td>
<td>Case series</td>
<td>USA</td>
<td>Salazar et al.</td>
<td>N/A</td>
<td>Convalescent plasma</td>
<td>To determine if transfusion of convalescent plasma is a safe treatment option for those with severe COVID-19 disease</td>
</tr>
<tr>
<td>1 May 2020</td>
<td>Clinical and Experimental Immunology</td>
<td>Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19</td>
<td>Pilot prospective</td>
<td>CT</td>
<td>Italy S. Sciacca, et al.</td>
<td>NA</td>
<td>Tocilizumab</td>
<td>To assess the efficacy and safety of tocilizumab in severe COVID-19 patients</td>
</tr>
<tr>
<td>Preprint</td>
<td>Pharmacological Research</td>
<td>Compassionate remdesivir treatment of severe COVID-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post treatment hospitalisation status</td>
<td>Case series</td>
<td>Italy</td>
<td>Spivakko Anticor, et al.</td>
<td>NA</td>
<td>Remdesivir</td>
<td>Comparative efficacy of remdesivir in ICU and non-ICU patients</td>
</tr>
<tr>
<td>25 April 2020</td>
<td>Cochrane Library</td>
<td>Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff</td>
<td>Systematic Review</td>
<td>International Collaboration</td>
<td>Verbek HJ, et al.</td>
<td>NA</td>
<td>PPE</td>
<td>To evaluate which type of full-body PPE and which method of donning or doffing PPE have the least risk of contamination or infection for HCW, and which training methods increase compliance with PPE protocols</td>
</tr>
<tr>
<td>14 May 2020</td>
<td>Cochrane Library</td>
<td>Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A rapid review</td>
<td>Systematic Review</td>
<td>Netherlands</td>
<td>Veld Si, et al.</td>
<td>NA</td>
<td>Convalescent Plasma</td>
<td>To assess whether convalescent plasma or hyperimmune immunoglobulin transfection is effective and safe in the treatment of people with COVID-19</td>
</tr>
</tbody>
</table>

08 May 2020 MedRxiv dPCR: a more sensitive and accurate tool for SARS-CoV-2 detection in low viral load specimens Clinical evaluation of diagnostic test China Suo et al. https://www.medrxiv.org/content/10.1101/2020.04.03.20091672 v2 full text PCR diagnostic test To compare the dynamic range and the limit of detection (LoD) between dPCR and RT-PCR

05 May 2020 MedRxiv Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomised, Controlled Trial RCT China Yan Lou et al. https://www.medrxiv.org/content/10.1101/2020.05.01.20091672 v2 full text CHCTR20000295 S44 Baloxavir marboxil, favipiravir To evaluate the efficacy and safety of adding baloxavir marboxil or favipiravir to the current standard anti-viral treatment

11 May 2020 MedRxiv Celebrex (Celecoxib) and Tocilizumab: a Real-World Experience in the Treatment of COVID-19 Outcomes Study, Italy, China, Spain Retrospective observational study Italy Ceppa et al. https://www.medrxiv.org/content/10.1101/2020.05.01.20091672 v2 full text N/A Tocilizumab To determine if previous exposure to Celecoxib and tocilizumab at time of COVID-19 diagnosis influences clinical outcomes

05 May 2020 MedRxiv Efficacy of face mask in preventing respiratory virus transmission: a systematic review and meta-analysis Systematic review and meta-analysis China Liang et al. https://www.medrxiv.org/content/10.1101/2020.05.01.20091672 v2 full text N/A Facemask To evaluate the effectiveness of the use of masks to prevent laboratory-confirmed respiratory virus transmission.

5 May 2020 Nature Impact of corticosteroids on outcomes of patients with SARS-CoV-2, SARS-CoV, or MERS-CoV infections: a systematic review and meta-analysis Meta-analysis China Huan Li et al. https://www.nature.com/articles/s41591-020-02416-y v3 full text NA Corticosteroids Evaluate the safety and efficacy of corticosteroids on SARS-CoV-2, SARS-CoV, and MERS-CoV infections

Preprint Journal of Biomedical and Health Informatics In Silico Trial to test COVID-19 candidate vaccines: a case study with USPff platform Analytical modeling Italy Giuli Russo, et al https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246497 v2 full text NA Vaccine Can an efficient in-silico trial be developed, and can it evaluate vaccine candidates?


29 April 2020 Autoimmune Reviews Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis Retrospective analysis Israel Omer Gendelman, et al. https://www.oasr.org/article/S0272-9296(20)30265-8 v3 full text NA Colchicine, hydroxychloroquine Protective role of colchicine or hydroxychloroquine for COVID19 infection


08 May 2020 The Lancet Triple combination of interferon beta-1b, loxoprof–ribavirin, and ribavirin in the treatment of patients admitted to hospital with COVID-19 in a hospital, randomised, phase 2 trial Retrospective analysis Hong Kong Hung et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30472-6 v3 full text NA Interferon beta-1b, loxoprof–ribavirin Tocilizumab The efficacy and safety of combination

07 May 2020 The Lancet Rheumatology Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Retrospective analysis Italy Cavalli et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30472-6 v2 full text NA Tocilizumab, anakinra Efficacy of anakinra


05 May 2020 BMJ Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data Observation of study France Mahévos et al. https://www.bmj.com/content/370/bmj.m1569 v2 full text NA Hydroxychloroquine Is hydroxychloroquine effective?
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>01 May</td>
<td>medRxiv</td>
<td>Review and methodological analysis of trials currently testing treatment and prevention options for the novel coronavirus disease (COVID-19) globally.</td>
<td>Systematic review</td>
<td>Greece, France</td>
<td>Fragkou et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.04.27.20077398v1.full.pdf">https://www.medrxiv.org/content/10.1101/2020.04.27.20077398v1.full.pdf</a></td>
<td>NA</td>
<td>all treatment and prevention options for COVID-19</td>
<td>To summarise the data on all currently tested treatment and prevention options for COVID-19, and to methodologically analyse and evaluate the quality of the registered interventional studies</td>
</tr>
<tr>
<td>01 May</td>
<td>medRxiv</td>
<td>Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19</td>
<td>Retrospective e analysis</td>
<td>China</td>
<td>Bo Yu et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.04.27.20077886v1.full.pdf">https://www.medrxiv.org/content/10.1101/2020.04.27.20077886v1.full.pdf</a></td>
<td>NA</td>
<td>Hydroxychloroquine</td>
<td>Could hydroxychloroquine administration be beneficial in the treatment of critically ill patients with COVID-19?</td>
</tr>
<tr>
<td>29 April</td>
<td>medRxiv</td>
<td>Hypertension and Renin-Angiotensin Aldosterone System in Patients with COVID-19</td>
<td>Retrospective e analysis</td>
<td>USA</td>
<td>Ip et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.04.24.20077788v1.full.pdf">https://www.medrxiv.org/content/10.1101/2020.04.24.20077788v1.full.pdf</a></td>
<td>NA</td>
<td>anti-hypertensive agents</td>
<td>To determine if anti-hypertensive drugs are harmful to beneficial to Covid-19 patients with hypertension</td>
</tr>
<tr>
<td>29 April</td>
<td>medRxiv</td>
<td>Concentration-dependent mortality of chloroquine in overdose</td>
<td>Retrospective analysis, Bayesian logistic regression, pharmacodynamic modeling</td>
<td>Thailand/UK/France</td>
<td>Watson et al.</td>
<td><a href="https://www.medrxiv.org/content/10.1101/2020.04.24.20073615v1.full.pdf">https://www.medrxiv.org/content/10.1101/2020.04.24.20073615v1.full.pdf</a></td>
<td>NA</td>
<td>Chloroquine</td>
<td>To evaluate the risk of overdose for chloroquine treatment or prevention regimens currently being trialed in COVID19</td>
</tr>
</tbody>
</table>
A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.

Systematic review
USA
Chawdhry et al.
NA
NA
Analyze current literature to find the role of CQ and HCQ

Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A Multicenter Retrospective Cohort Study

Retrospective cohort study
China
Ziyu Shao et al.
NA
Intravenous immunoglobulin (IVIG) therapy
To determine the clinical efficacy of intravenous immunoglobulin (IVIG) therapy in COVID-19 patients.

Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation.

Pharmacokinetic (PK-PD) model
Netherlands
Verschoor et al.
NA
Chloroquine
To establish best-evidence to inform pediatric Chloroquine dosage for children infected with COVID-19

Effect of High vs Low Doses of Chloroquine Phosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.

RCT
Brazil
Borba et al.
https://jama.ama-assn.org/content/325/22/276545.full.pdf
NCT04323517
Chloroquine
To evaluate the safety & efficacy of different dosages of chloroquine in patients with severe COVID-19.

A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of a-Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19)

RCT
China
Zhong et al.
ChCTR2000029851
a-Lipoic acid (ALA)
To evaluate the clinical efficacy and safety of a-Lipoic acid (ALA) for critically ill patients with COVID-19.

Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis

Rapid review and meta-analysis
China
Shuya Lu et al.
NA
Glucocorticoids
To systematically review and summarize the current evidence of the effectiveness and safety of glucocorticoid therapy for patients with COVID-19

A systematic review of Aravirak, Tocilizumab, Sarilumab and Silvastatin for coronavirus-related infections

Systematic review
UK
Khan et al.
N/A
Aravirak, Tocilizumab, Sarilumab, Silvastatin
To assess the effectiveness of specific interleukin-1 and -6 inhibitors for the treatment of coronavirus-related infections.

Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND

Preliminary results from clinical trial
USA
CytoDyn INC
N/A
Leronlimab
Could leronlimab be effective?

Transplantation of ACE2+-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

Observational study
China
Leng et al.
ChCTR2000029890
ACE2+-mesenchymal stem cell
Efficacy of MSC transplantation in COVID-19 patients

Association of Imitant Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

Observational study
China
Zhang et al.
https://www.plone.org/content/10.1151/clinres/0040-1211.2020.001276
NA
Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs)
To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in COVID-19 patients with hypertension

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Case series
China
Juy Li et al
https://jama.ama-assn.org/content/325/22/276549.full.pdf
NA
Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs)
Asses the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection.

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

RCT
China
Xianyan Liu et al.
https://www.stke胄meas.org/content/10.1126/stke.20201127
NA
Dipyridamole
Is treatment with dipyridamole clinically effective in severely ill COVID-19 patients?

Benefits and Risks of Chloroquine and Hydroxychloroquine in The Treatment of Viral Diseases: A Meta-Analysis of Placebo Randomized Controlled Trials

meta-analysis of RCTs
China/ USA
Jing Wang et al.
NA
chloroquine/hydroxychloroquine
To evaluate the efficacy and safety of Chloroquine and hydroxychloroquine

Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 2 – Hand hygiene and other hygiene measures: systematic review and meta-analysis.

Systematic review and meta-analysis
Saudi Arabia, Australia, Canada, Al-Ansary
NA
Hygiene interventions
To assess the effectiveness of hand hygiene, surface disinfecting, and other hygiene interventions in preventing or reducing the spread of illnesses from respiratory viruses

An experimental trial of recombinant human interferon-alpha nasal drops to prevent coronavirus disease 2019 in medical staff in a epidemic area

Clinical trial
China
Meng et al.
NCT04320238
Recombinant human interferon-alpha nasal drops
To investigate the efficacy and safety of recombinant human interferon-alpha nasal drops in healthy medical staff to prevent COVID-19.

An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELAC01)

RCT
China
Li et al.
NCT04252885
lopinavir/ritonavir (Kaltra), arbidol
Lopinavir/Ritonavir combination compared to Arbidol compared to no antiretroviral treatment

Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis

review and meta-analysis
China
Shi et al.
N/A
Antivirals
To assess the potential effectiveness and safety of antiviral agents for COVID-19 in children.
<table>
<thead>
<tr>
<th>Date</th>
<th>Source</th>
<th>Title</th>
<th>Methodology</th>
<th>Country</th>
<th>Authors</th>
<th>Study Type</th>
<th>Evidence Type</th>
<th>Key Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>17 April 2020</td>
<td>medRxiv</td>
<td>Efficacy and Safety of Antibiotic Agents in Children with COVID-19: A Rapid Review</td>
<td>rapid review</td>
<td>China</td>
<td>Wang et al.</td>
<td>NA</td>
<td>antibiotics</td>
<td>The aim of this review was to evaluate the efficacy and safety of antibiotic agents in children with COVID-19</td>
</tr>
<tr>
<td>24 March 2020</td>
<td>Preprint</td>
<td>No evidence of rapid antiviral clearance or clinical benifit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection</td>
<td>prospective virological assay</td>
<td>France</td>
<td>JM Molina et al.</td>
<td>NA</td>
<td>NA</td>
<td>Is hydroxychloroquine effective for viral clearance when reproducing the study of Gaudret et al.?</td>
</tr>
<tr>
<td>Preprint</td>
<td>Clinical Infectious Diseases</td>
<td>Towards Optimisation of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients</td>
<td>prospective PK study</td>
<td>France</td>
<td>Sophie Perrinel et al.</td>
<td>NA</td>
<td>Hydroxychloroquine</td>
<td>What is the best dose of hydroxychloroquine for COVID19 patients?</td>
</tr>
<tr>
<td>10 April 2020</td>
<td>NEJM</td>
<td>Compassionate Use of Remdesivir for Patients with Severe Covid-19</td>
<td>report</td>
<td>UK, Canada, Europe, Japan</td>
<td>Grein et al.</td>
<td>NA</td>
<td>Remdesivir</td>
<td>NA</td>
</tr>
<tr>
<td>10 March 2020</td>
<td>Complementa ry Therapies in Clinical Practice</td>
<td>Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study</td>
<td>non-interventional RCT</td>
<td>China</td>
<td>Kai Liu, et al.</td>
<td>Respiratory rehabilitation training</td>
<td>NA</td>
<td>Investigate the effects of 6-week respiratory rehabilitation training on respiratory function, QoL, mobility and psychological function in elderly patients with COVID-19</td>
</tr>
<tr>
<td>07 April 2020</td>
<td>MedRxiv</td>
<td>The potential of low-molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study</td>
<td>retrospective analysis</td>
<td>China</td>
<td>Chen Shi et al.</td>
<td>Not found</td>
<td>Enoxaparin</td>
<td>Efficacy of enoxaparin</td>
</tr>
<tr>
<td>14 April 2020</td>
<td>MedRxiv</td>
<td>No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen support: results of a study using routinely collected data to emulate a target trial</td>
<td>retrospective analysis</td>
<td>France</td>
<td>Matthaiu Mahendran et al.</td>
<td>NA</td>
<td>Hydroxychloroquine</td>
<td>To assess the effectiveness of hydroxychloroquine in patients with severe COVID-19</td>
</tr>
<tr>
<td>Date</td>
<td>Journal</td>
<td>Title</td>
<td>Design/Methodology</td>
<td>Region(s)</td>
<td>Participants</td>
<td>Intervention</td>
<td>Outcomes</td>
<td>Funding/Collaborations</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>-------------</td>
<td>----------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>27 March 2020</td>
<td>JAMA</td>
<td>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</td>
<td>Observation of therapeutic control China C Shen et al.</td>
<td>China</td>
<td>5 patients</td>
<td>Convalescent plasma</td>
<td>Plasma is beneficial for critically ill COVID-19 patients?</td>
<td>N/A</td>
</tr>
<tr>
<td>6 April 2020</td>
<td>Proceedings of the National Academy of Sciences of the United States of America</td>
<td>The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study</td>
<td>Observation of therapeutic control China Kai Quan et al.</td>
<td>China</td>
<td>6 patients</td>
<td>Convalescent plasma</td>
<td>Plasma is beneficial for COVID-19 patients?</td>
<td>N/A</td>
</tr>
<tr>
<td>Preprint</td>
<td>Influenza and other Respiratory Viruses</td>
<td>Medical Masks vs N95 Respirators for Preventing COVID-19 in Health Care Workers: A Systematic Review and Meta-Analysis of Randomized Trials</td>
<td>Systematic review Canada Jessica J Bartoshko et al.</td>
<td>Canada</td>
<td>647 participants</td>
<td>N95 respirators vs surgical masks</td>
<td>Compare medical masks to N95 respirators in preventing laboratory confirmed viral infection and respiratory illness involving coronavirus specifically in health care workers.</td>
<td>N/A</td>
</tr>
<tr>
<td>Preprint</td>
<td>Disaster Medicine and Public Health Preparedness</td>
<td>RANDOMIZED TRIAL OF INSTRUCTOR-LED TRAINING VERSUS VIDEO LESSON IN TRAINING HEALTH-CARE PROVIDERS IN PROPER DONNING AND DOFFING OF PERSONAL PROTECTIVE EQUIPMENT</td>
<td>RCT Denmark J Christensen et al.</td>
<td>Denmark</td>
<td>2 groups</td>
<td>Training on personal protective equipment</td>
<td>Is attending one live training session or watching video trainings over a month more effective for training on donning and doffing personal protective equipment?</td>
<td>N/A</td>
</tr>
<tr>
<td>Preprint</td>
<td>Journal of Medical Virology</td>
<td>Performance of ViralDiagTM COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department</td>
<td>Diagnostic assay Italy Irene Cassanetti et al.</td>
<td>Italy</td>
<td>168 patients</td>
<td>N/A</td>
<td>To assess an easy to perform serological assay for diagnosis of COVID-19</td>
<td>N/A</td>
</tr>
<tr>
<td>Preprint</td>
<td>Journal of Clinical Microbiology</td>
<td>Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2</td>
<td>Diagnostic assay China Weiping Liu et al.</td>
<td>China</td>
<td>800 patients</td>
<td>N/A</td>
<td>Evaluate the diagnostic feasibility of two ELISA assays</td>
<td>N/A</td>
</tr>
<tr>
<td>Article-originally published in 2015; authors added comment on 10/05/2020</td>
<td>BMJ Open</td>
<td>A cluster randomised trial of cloth masks compared with medical masks in healthcare workers</td>
<td>RCT Australia /Vietnam Mackaytre CR et al.</td>
<td>Australia /Vietnam</td>
<td>36 participants</td>
<td>Medical masks, cloth masks</td>
<td>To compare the efficacy of cloth masks to medical masks in hospital healthcare workers</td>
<td>N/A</td>
</tr>
<tr>
<td>31 March 2020</td>
<td>MedRxiv</td>
<td>Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial</td>
<td>RCT China Dheswai Chen et al.</td>
<td>China</td>
<td>559 patients</td>
<td>Hydroxychloroquine</td>
<td>Assess the efficacy of hydroxychloroquine</td>
<td>N/A</td>
</tr>
<tr>
<td>Preprint</td>
<td>Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow-up: an observational study</td>
<td>RCT France Gautret et al.</td>
<td>France</td>
<td>80 patients</td>
<td>Hydroxychloroquine, Azithromycin</td>
<td>Assess the efficacy of hydroxychloroquine associated with azithromycin</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Source</td>
<td>Title</td>
<td>Study Design</td>
<td>Countries</td>
<td>Participants</td>
<td>Intervention(s)</td>
<td>Comparison</td>
<td>Results/Findings</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>23 March 2020</td>
<td>Bmj</td>
<td>An exploratory, randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (LEACOII)</td>
<td>RCT</td>
<td>China</td>
<td>279</td>
<td>Lopinavir/ritonavir (Kaletra), arbidol</td>
<td>Lopinavir-Ritonavir combination compared to Arbidol compared to no antiviral treatment</td>
<td>NCT04252885</td>
</tr>
<tr>
<td>10 Feb 2020</td>
<td>Biosci Trends</td>
<td>Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.</td>
<td>Summary of 15 CTs</td>
<td>China</td>
<td></td>
<td>Chloroquine</td>
<td>Could chloroquine be effective?</td>
<td></td>
</tr>
<tr>
<td>30 March 2020</td>
<td>not published yet</td>
<td>Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients</td>
<td>Preliminary results from clinical trial</td>
<td>USA</td>
<td></td>
<td>CytoDyn Inc.</td>
<td>NA Leronlimab</td>
<td>Could leronlimab be effective?</td>
</tr>
<tr>
<td>27 March 2020</td>
<td>medRxiv</td>
<td>Faripiravir versus Arbidol for COVID-19: A Randomized Clinical Trial</td>
<td>RCT</td>
<td>China</td>
<td></td>
<td>Faripiravir, Arbidol</td>
<td>Conventional therapy + favipiravir or arbidol</td>
<td></td>
</tr>
<tr>
<td>11 March 2020</td>
<td>Journal of Infection</td>
<td>Arbidol combined with LPS/β versus LPS/β alone against Corona Virus Disease 2019: A retrospective cohort study</td>
<td>Retrospective cohort study</td>
<td>China</td>
<td></td>
<td>Lopinavir/ritonavir, Arbidol</td>
<td>Arbidol and lopinavir-ritonavir compared to lopinavir-ritonavir only?</td>
<td></td>
</tr>
<tr>
<td>In press</td>
<td>British Journal of Anaesthesia</td>
<td>High-flow nasal-oxygenation-assisted fiberoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial</td>
<td>RCT</td>
<td>China</td>
<td></td>
<td>High-flow nasal oxygenation</td>
<td>What is the efficacy and safety of high-flow nasal oxygenation during fiberoptic bronchoscopic intubation in critically ill patients with COVID-19?</td>
<td></td>
</tr>
<tr>
<td>2020 Pre-print online</td>
<td>Chinese Journal of Infectious Diseases</td>
<td>Efficacy of lopinavir, ritonavir and Arbidol for the treatment of new coronavirus pneumonia</td>
<td>Retrospective analysis</td>
<td>China</td>
<td></td>
<td>Lopinavir/ritonavir, Arbidol</td>
<td>Efficacy of lopinavir/ritonavir and arbidol</td>
<td></td>
</tr>
<tr>
<td>2020 Pre-print</td>
<td>MedRxiv</td>
<td>Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial</td>
<td>CT</td>
<td>China</td>
<td></td>
<td>Meplazumab</td>
<td>Assess the efficacy and safety of meplazumab, a humanized anti-COVID19 antibody, as an add-on therapy in patients with COVID-19 pneumonia.</td>
<td></td>
</tr>
</tbody>
</table>